Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
The US major is investing over $360m in new money into the UK but the country has being losing its lustre as an appealing place to invest since Brexit and needs to offer more to multinationals.
Impressed by the data to date on bexicaserin for epileptic encephalopathies syndromes, the Danish drugmaker hopes the drug, through the acquisition of Longboard, will become a cornerstone of its new neuro-rare disease franchise.
The French major and partner Denali's attempts to validate RIPK1 as a promising target have once again foundered as oditrasertib comes up short in a multiple sclerosis trial months after a failure in amyotrophic lateral sclerosis.
While vatiquinone may have missed its primary endpoint in a Phase III trial, PTC is ready to file the drug for the debilitating, life-shortening disorder after showing that it slowed disease progression over 144 weeks.
Deal Snapshot: The Cambridge, UK-based company could be in line for payments just shy of $2bn if its partnership with the US giant comes up trumps.
The Avillion-partnered treatment has succeeded in the BATURA trial, adding to the body of evidence supporting Airsupra as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of disease severity.